Exact Sciences' Shares Take a Hit Following Colorectal Cancer Dx Presentation
October 29, 2010
Exact Sciences' Shares Take a Hit Following Colorectal Cancer Dx Presentation
In results reported Thursday, the company said that its Cologuard test achieved of 64 percent sensitivity for pre-cancers and 85 percent for cancer and a specificity of 88 percent.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.